Back

Determinants of pulmonary vascular resistance reduction with upfront oral therapy in idiopathic pulmonary arterial hypertension: relevance in risk assessment

1 September 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Advances in the Management of Pulmonary Arterial Hypertension Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Associate Professor Roberto Badagliacca

Sapienza University of Rome, Rome (Italy)

2 More presentations in this session

Presentation thumbnail
Outcomes associated with modern treatment paradigms in connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH): a meta-analysis of randomized controlled trials (RCTs)
Doctor V. McLaughlin (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil
Doctor R. Sadushi-Kolici (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in the Management of Pulmonary Arterial Hypertension

The Event

Event poster

ESC Congress 2020

1 September 2020 08:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources